Merck says US rejects its MS drug

German pharmaceutical group Merck KgaA said Wednesday that the US Food and Drug Administration (FDA) has refused to approve use of its multiple sclerosis treatment Cladribine.

The FDA declined to approve the drug "in its present form" and asked Merck to "provide an improved understanding of the safety risks and the overall benefit-risk profile," either through additional analyses or studies.

said it would ask the US regulator to clarify the next steps and will try to address its questions.

The German pharmaceutical group has already been rebuffed by European regulators and has only received authorisation to sell Cladribine in Australia and Russia.

Shares in the company were down 0.65 percent to 64.58 euros in early trade on the Frankfurt stock exchange where the DAX index was off 0.91 percent overall.


Explore further

Clinical Data gets app nod for depression drug

(c) 2011 AFP

Citation: Merck says US rejects its MS drug (2011, March 2) retrieved 12 November 2019 from https://medicalxpress.com/news/2011-03-merck-ms-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments